Top Markets
Coin of the day
Bristol-Myers Squibb Company Bristol-Myers Squibb Company

Bristol-Myers Squibb Company

BMY
Helyezés a részvények között #174
Bristol-Myers Squibb Company operates as a global biopharmaceutical entity,... Bristol-Myers Squibb Company operates as a global biopharmaceutical entity, actively involved in the research, development, licensing, production, and worldwide commercialization of its medicinal portfolio. The company's therapeutic areas span hematology, oncology, cardiovascular health, immunology, fibrotic conditions, neuroscience, and infectious diseases like COVID-19. Its significant pharmaceutical offerings include Revlimid, an oral immunomodulatory agent for multiple myeloma, and Eliquis, an oral anticoagulant crucial for reducing stroke risk and systemic embolism in non-valvular atrial fibrillation, as well as treating deep vein thrombosis and pulmonary embolism. The portfolio also features Opdivo, utilized across various anti-cancer indications; Pomalyst/Imnovid, prescribed for multiple myeloma patients; and Orencia, targeting active rheumatoid arthritis and psoriatic arthritis in adults. Other key therapies are Sprycel, employed in the management of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy, indicated for patients with unresectable or metastatic melanoma; and Abraxane, a protein-bound chemotherapy formulation. Furthermore, Bristol-Myers Squibb offers Reblozyl, addressing anemia in adult patients with beta thalassemia; Empliciti, another treatment option for multiple myeloma; and Zeposia, designed to treat relapsing forms of multiple sclerosis. Revolutionary treatments like Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for adult patients battling relapsed or refractory large B-cell lymphoma, are also part of its lineup. Completing its product range are Inrebic, an oral kinase inhibitor specifically for adult myelofibrosis, and Onureg, used in the treatment of adult patients with acute myeloid leukemia (AML). Bristol-Myers Squibb distributes its pharmaceutical products through a diverse network encompassing wholesalers, distributors, pharmacies, retail outlets, hospitals, clinics, and governmental organizations. Founded in 1887 and formerly known as Bristol-Myers Company, the firm maintains its headquarters in New York, New York.
Részvényárfolyam
$62.26
Utolsó szinkronizálás: 2026-09-22
Piaci kapitalizáció
$127.18B
Változás (1 nap)
-0.78%
Változás (1 év)
38.63%
Ország
US
Kereskedés Bristol-Myers Squibb Company (BMY)

Kategória

Bristol-Myers Squibb Company (BMY) nyeresége
Nyereség ekkor: Jun 2026 TTM: $11.91B
Bristol-Myers Squibb Company legfrissebb pénzügyi jelentései szerint a vállalat jelenlegi nyeresége $11.91B. 2024 évben a vállalat $-8.38B nyereséget ért el, csökkenés a 2023 év nyereségéhez, amely $8.44B volt. Az ezen az oldalon megjelenített nyereség a kamatok és adók előtti eredmény, azaz EBIT.
Bristol-Myers Squibb Company nyereségtörténete 2000 és 2026 között
Nyereség az év végén
Év Nyereség Változtassa meg
2026 (TTM) $11.91B 27.68%
2025 $9.33B -211.33%
2024 $-8.38B -199.28%
2023 $8.44B 9.43%
2022 $7.71B -4.75%
2021 $8.10B -217.86%
2020 $-6.87B -238.11%
2019 $4.98B -16.64%
2018 $5.97B 16.31%
2017 $5.13B -13.25%
2016 $5.92B 184.79%
2015 $2.08B -12.77%
2014 $2.38B -17.64%
2013 $2.89B 23.55%
2012 $2.34B -66.48%
2011 $6.98B 14.99%
2010 $6.07B 8.37%
2009 $5.60B 17.29%
2008 $4.78B 35.14%
2007 $3.53B 47.25%
2006 $2.40B -44.24%
2005 $4.30B -2.58%
2004 $4.42B -5.60%
2003 $4.68B 69.50%
2002 $2.76B 24.48%
2001 $2.22B -59.51%
2000 $5.48B 0.00%
Hasonló cégek vagy versenytársak nyeresége
Vállalat Nyereség Nyereségkülönbség Ország
$33.60B 182.08%
US
$25.20B 111.55%
US
$8.70B -26.96%
US
$21.39B 79.58%
CH
$5.95B -50.06%
US